Evidence Tiers at a Glance

HBOT research spans several evidence tiers depending on the indication. The strongest clinical evidence is tied to the Undersea and Hyperbaric Medical Society (UHMS) list of approved indications — which carries Medicare/CMS reimbursement in the US. Neurological HBOT (TBI, stroke, long COVID) is supported by growing RCT evidence but remains off-label. A third category — autism, PTSD, anti-aging — remains investigational with limited RCT support.

Tier 1 — UHMS-Approved Indications (High Evidence)

  • Decompression sickness & arterial gas embolism — US Navy Treatment Table 6 is the standard of care; decades of clinical use dating to the 1940s.
  • Carbon monoxide poisoning — Weaver et al. 2002 NEJM RCT established the three-session Weaver protocol; demonstrated reduction in delayed neurocognitive sequelae at 6 weeks and 12 months.
  • Diabetic foot ulcers (Wagner Grade 3+) — Multiple RCTs (Löndahl 2010, Faglia 1996, Abidia 2003); meta-analyses consistently show improved healing rates and reduced amputation. CMS reimbursed at 2.4 ATA.
  • Delayed radiation injury — Marx et al. (osteoradionecrosis prophylaxis) and Clarke et al. 2008 (radiation cystitis/proctitis) established HBOT for post-radiation tissue injury.
  • Compromised skin grafts and flaps — Multiple case series; routine adjunct for threatened grafts.
  • Chronic refractory osteomyelitis — Cochrane review supports HBOT as adjunct to standard antibiotic/surgical care.
  • Necrotising soft-tissue infection — adjunct to surgical debridement and antibiotics; retrospective evidence supports mortality reduction.
  • Crush injury & acute traumatic ischaemia — Bouachour 1996 RCT showed improved wound healing in severe crush injury.
  • Thermal burns, intracranial abscess, sudden sensorineural hearing loss, severe anaemia, clostridial myonecrosis — all UHMS-approved with case-series or small-trial support.

Tier 2 — Research-Stage Indications (Moderate Evidence)

  • Traumatic brain injury (TBI) — Hadanny & Efrati 2020; Tal et al. 2017 (crossover design); Boussi-Gross et al. 2013. Significant cognitive improvement at 2.0 ATA over 40–60 sessions in mild-to-moderate TBI, including chronic cases years post-injury. Response in approximately 60–80% of participants.
  • Stroke recovery (chronic phase) — Boussi-Gross et al. 2013 PLoS ONE RCT showed cognitive and functional gains 6–36 months post-stroke. Follow-up imaging demonstrated improved cerebral perfusion in previously hypoperfused regions.
  • Long COVID / PASC — Zilberman-Itskovich et al. 2022 RCT showed significant improvements in cognitive function, physical measures, and quality of life after 40 sessions at 2.0 ATA. Sham-controlled design.
  • Fibromyalgia — Efrati et al. 2015 showed symptom reduction and brain-imaging changes at 2.0 ATA over 40 sessions. Participants also reduced analgesic medication use.
  • Age-related cognitive decline — Hadanny et al. 2020 (Aging) demonstrated cognitive gains in healthy older adults at 2.0 ATA over 60 sessions.

Tier 3 — Investigational Indications (Limited Evidence)

  • PTSD — Harch et al. 2017 trial in veterans; mixed results across larger trials. Signal exists but RCT evidence remains inconsistent.
  • Autism spectrum disorder — Rossignol et al. 2009 initial RCT at 1.3 ATA; follow-up trials have shown inconsistent effects. Pressure specification critical to interpretation.
  • Anti-aging / longevity — Hachmo et al. 2020 showed telomere length changes after HBOT; mechanistically interesting but clinical significance uncertain.
  • Sports recovery — Mostly case series and small trials; no large RCT evidence to support routine use.
  • Lyme disease, chronic fatigue, Alzheimer's disease — Early-stage research only; should be considered experimental.

Core Mechanisms of HBOT

Understanding HBOT research requires familiarity with the underlying mechanisms. These are the primary biological pathways through which hyperbaric oxygen produces clinical effects:

1. Elevated Dissolved Oxygen (Primary Effect)

At 1 ATA breathing room air, arterial oxygen tension (PaO₂) is around 100 mmHg. At 2.0 ATA breathing 100% O₂, PaO₂ exceeds 1,000 mmHg — a ten-fold increase. The extra dissolved oxygen in plasma bypasses haemoglobin-dependent delivery and reaches hypoperfused or ischaemic tissue by simple diffusion.

2. Angiogenesis via HIF-1α Stabilisation

Paradoxically, intermittent high-oxygen exposure stabilises hypoxia-inducible factor 1-alpha (HIF-1α) via oxidative stress signalling. HIF-1α drives downstream expression of VEGF, SDF-1, and other pro-angiogenic factors. The result: new capillary formation in chronically hypoperfused tissue — the core mechanism in wound healing and neurological recovery.

3. Stem Cell Mobilisation

Thom et al. 2006 and subsequent work demonstrated that HBOT mobilises CD34+ bone marrow stem/progenitor cells into circulation after approximately 20 sessions. These cells home to sites of tissue injury and contribute to repair.

4. Mitochondrial Function

HBOT upregulates mitochondrial biogenesis via PGC-1α and improves oxidative phosphorylation efficiency. This is particularly relevant to post-ischaemic injury (stroke, TBI) where mitochondrial dysfunction is a key pathological feature.

5. Antimicrobial Effects

High oxygen tension is directly bactericidal to anaerobes (clostridia) and enhances neutrophil-mediated oxidative killing of aerobic bacteria. This mechanism underpins HBOT's role in gas gangrene, necrotising infection, and refractory osteomyelitis.

6. Neuroinflammation Modulation

HBOT reduces microglial activation and shifts macrophage polarisation towards the M2 (reparative) phenotype. In TBI and long COVID this appears central to the observed clinical benefit.

Key Meta-Analyses & Systematic Reviews

  • Cochrane Review — HBOT for diabetic foot ulcers (Kranke et al. 2015) — Found evidence of improved healing at 6 weeks with HBOT as adjunct to standard care.
  • Cochrane Review — HBOT for carbon monoxide poisoning (Buckley et al. 2011) — Noted mixed trial quality; the Weaver 2002 trial remains the most methodologically sound.
  • Hadanny & Efrati 2020 (Nature review) — Comprehensive review of HBOT in neurological conditions, synthesising a decade of RCT evidence from the Sagol Center.
  • UHMS Indications Manual (14th edition, 2019) — The definitive reference for approved indications; updated periodically.
  • Mathieu et al. 2017 (European Committee for Hyperbaric Medicine consensus) — The European counterpart to UHMS; largely overlapping indications list.

Leading Research Groups

  • Shai Efrati Lab (Tel Aviv University, Sagol Center for Hyperbaric Medicine) — The leading HBOT research group globally for neurological indications. Publications across TBI, stroke, long COVID, fibromyalgia, longevity, and age-related cognitive decline. Houses the largest neurological HBOT RCT programme in the world.
  • Paul Harch (LSU) — US-based clinician-researcher; early post-concussion and TBI work in veteran populations.
  • Lindell Weaver (Intermountain, Utah) — Established the Weaver carbon monoxide protocol and remains active in CO and wound-care trials.
  • Richard Moon (Duke) — Diving and hyperbaric medicine; UHMS Center of Excellence.
  • UCSD Hyperbaric Medicine Program — Clinical trials in wound care and neurological HBOT.
  • Karolinska Institute (Sweden) & University of Lund (Löndahl) — Diabetic foot ulcer trials establishing much of the European evidence base.

How to Evaluate HBOT Trial Evidence

Not all HBOT trials are equally rigorous. When reading HBOT literature, pay attention to:

Pressure Specification

A trial at 1.3 ATA with 85–95% oxygen via concentrator is a different intervention from one at 2.0 ATA with 100% medical-grade oxygen. Pressure and FiO₂ determine arterial oxygen tension — the primary biological driver. Always confirm both.

Course Length

Most positive neurological trials deliver 40–60 sessions. Shorter courses (10–20 sessions) may miss the delayed neuroplastic effects that accumulate later in a course and in follow-up. A null result at 20 sessions is not the same as a null result at 60.

Sham Design

True sham HBOT is challenging. Any pressurisation produces identifiable sensations (ear fullness, warmth). Trials typically use low-pressure (e.g. 1.1 ATA) sham arms with air. Review the sham protocol — a 1.3 ATA "sham" that itself has biological activity will narrow the apparent effect size of the active arm.

Follow-up Window

Neurological gains from HBOT often continue to accumulate 1–3 months post-treatment, consistent with delayed neuroplastic effects. Trials with end-of-course assessments only will underestimate the long-term benefit.

Outcome Measures

Subjective outcomes (quality of life, symptom scales) are important but prone to placebo contamination. Look for trials that pair subjective measures with objective ones — neurocognitive batteries, imaging (SPECT, perfusion MRI), TcPO₂ for wound healing.

Sample Size & Statistical Approach

Many HBOT trials are small (n=20–100). Effect sizes should be considered alongside confidence intervals, not just p-values. Pre-specified primary outcomes matter — post-hoc analyses that produce positive results should be interpreted cautiously.

Where to Search Primary Literature

  • PubMed — The primary biomedical literature database. Search terms: "hyperbaric oxygen" plus the indication of interest. Filter by article type (RCT, review, meta-analysis).
  • ClinicalTrials.gov — Active and completed trial registry. Search "hyperbaric oxygen" for current recruitment. See also our Clinical Trials Tracker.
  • UHMS — Undersea and Hyperbaric Medical Society indications manual and clinical practice guidelines. The authoritative source for US clinical practice.
  • Cochrane Library — Systematic reviews on specific HBOT indications. Multiple relevant reviews across wound care, CO poisoning, TBI, and more.
  • UHMS Undersea and Hyperbaric Medicine journal — The official UHMS journal; most HBOT clinical research publishes here or in Diving and Hyperbaric Medicine (SPUMS/EUBS joint journal).

Open Research Questions

Despite decades of clinical experience, significant open questions remain:

  • Optimal pressure for neurological indications — 2.0 ATA has the most evidence, but is it optimal? Boost pressures (2.2 ATA) and lower pressures (1.5 ATA) are both being studied.
  • Course length individualisation — most trials use fixed 40- or 60-session courses. Can imaging biomarkers or clinical response identify responders early?
  • Combination approaches — HBOT plus specific pharmacological or cognitive-rehabilitation adjuncts.
  • Mechanisms of durability — why do gains in some neurological indications appear durable while others regress? What predicts long-term response?
  • Paediatric and elderly protocols — most data comes from adults 25–65. Protocol adaptation for other age groups is understudied.

Research disclaimer: This library is a reference, not medical advice. Clinical decisions should always be made with a qualified physician familiar with the specific indication and the patient's full medical history.